Cell & Gene Therapy Market: Market Size & Forecast 2026

Cell and gene therapies represent a transformative category of precision medicines that address disease at the genetic or cellular level, rather than merely managing symptoms. The global market is valued at approximately $13.23 billion in 2025 and is expanding rapidly with a projected compound annual growth rate of 21.0%, as more therapies transition from clinical trials to commercial availability. These treatments span applications in oncology, rare genetic disorders, ophthalmology, and other therapeutic areas, with hundreds of clinical programs actively recruiting patients worldwide.

• •The market encompasses both in vivo gene therapies that deliver genetic material directly into the body and ex vivo cell therapies that modify cells outside the body before reinfusion
• •Unlike traditional pharmaceuticals, these treatments often provide durable or curative effects from a single administration, fundamentally altering long-term treatment economics
• •Manufacturing complexity and the personalized nature of many therapies have historically limited production scale, though industry-wide process improvements are gradually addressing these constraints

Accelerating regulatory approvals have been a primary catalyst, with agencies including the FDA, EMA, and PMDA establishing expedited pathways and clear approval frameworks for advanced therapy medicinal products. Rising global prevalence of cancer and diagnosed genetic disorders, combined with improved understanding of disease mechanisms, has expanded the addressable patient population and strengthened the value proposition for payers. Growing capital investment from pharmaceutical companies and dedicated biotechnology firms, alongside advances in viral vector technology and automated cell processing, is reducing production costs and enabling broader patient access.

• •Regulatory agencies have approved multiple CAR-T cell therapies and gene therapies for conditions including blood cancers, inherited retinal dystrophy, and spinal muscular atrophy, validating the therapeutic platform
• •Favorable reimbursement policies and rising healthcare expenditure in major markets are supporting commercial adoption despite high upfront treatment costs ranging from hundreds of thousands to over two million dollars per patient
• •Advances in CRISPR-Cas9 and other gene-editing technologies have expanded the range of treatable genetic conditions beyond ultra-rare diseases to more prevalent indications with larger patient populations

The market is broadly divided into cell therapy and gene therapy segments, with cell therapies currently commanding a larger revenue share driven by the commercial success of CAR-T treatments for hematologic malignancies. North America leads the global market, supported by a favorable regulatory environment, robust research infrastructure, and high healthcare spending, followed by Europe and the rapidly expanding Asia-Pacific region. The Asia-Pacific market is growing particularly quickly as countries including China, Japan, and South Korea enhance their regulatory frameworks, increase domestic manufacturing, and attract significant clinical trial investment.

• •Cell therapy products, particularly autologous CAR-T and stem cell therapies, currently dominate commercial sales, while gene therapies are gaining market share with increasing approvals for rare genetic diseases
• •North America accounts for the largest regional share, though Europe's established regulatory pathway through the EMA's advanced therapy framework and emerging markets in Asia-Pacific are capturing growing investment
• •In vivo gene therapies are emerging as a competitive alternative to ex vivo cell therapies due to simpler administration logistics and potentially lower manufacturing costs

What are the recent trends and outlook?

The market is shifting toward more accessible treatment modalities, with allogeneic cell therapies and in vivo gene therapies representing significant opportunities to reduce costs and simplify delivery compared to traditional autologous approaches. Manufacturing innovation, including automated cell processing, closed-system bioreactors, and standardized viral vector production platforms, is expected to improve scalability and reduce per-patient costs as the industry matures. Looking ahead, expansion into non-oncology indications such as autoimmune disorders, neurological diseases, and cardiovascular conditions is anticipated to significantly broaden the market beyond its current cancer-focused foundation.

• •Allogeneic and universal donor cell therapies are advancing through clinical trials, with the potential to reduce treatment costs from hundreds of thousands of dollars to more accessible price points
• •Next-generation gene-editing tools including base editing and prime editing are entering clinical development, offering improved precision and reduced off-target effects compared to earlier CRISPR approaches
• •The pipeline of late-stage candidates targeting prevalent diseases such as Parkinson's disease, heart failure, and type 1 diabetes could transform cell and gene therapy from niche treatments into mainstream therapeutic options